isradipine has been researched along with Cardiac Hypertrophy in 8 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a study of the effectiveness of isradipine, a calcium antagonist of the dihydropyridine group, in reversing left ventricular hypertrophy (LVH) in patients with mild-to-moderate hypertension." | 9.07 | Regression of left ventricular hypertrophy in the short-term treatment of hypertension with isradipine. ( Abreu, P; Ajzen, H; Plavnik, F; Portela, JE; Ramos, OL; Saragoça, MA; Vanneta, A, 1991) |
| "In view of the possibility that cardiac hypertrophy may be reversed by isradipine, we studied the effect of two different doses of isradipine (1." | 7.67 | Pump performance after regression of cardiac hypertrophy following treatment of hypertension with isradipine. ( Amorim, MP; Cezaretti, ML; de Almeida, JB; Portela, J; Ramos, OL; Saragoça, MA, 1989) |
| "This was a study of the effectiveness of isradipine, a calcium antagonist of the dihydropyridine group, in reversing left ventricular hypertrophy (LVH) in patients with mild-to-moderate hypertension." | 5.07 | Regression of left ventricular hypertrophy in the short-term treatment of hypertension with isradipine. ( Abreu, P; Ajzen, H; Plavnik, F; Portela, JE; Ramos, OL; Saragoça, MA; Vanneta, A, 1991) |
| "In view of the possibility that cardiac hypertrophy may be reversed by isradipine, we studied the effect of two different doses of isradipine (1." | 3.67 | Pump performance after regression of cardiac hypertrophy following treatment of hypertension with isradipine. ( Amorim, MP; Cezaretti, ML; de Almeida, JB; Portela, J; Ramos, OL; Saragoça, MA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Török, E | 1 |
| Borbás, S | 1 |
| Lengyel, M | 1 |
| Zorándi, A | 1 |
| Saragoça, MA | 3 |
| Portela, JE | 2 |
| Abreu, P | 2 |
| Plavnik, F | 2 |
| Ventura, R | 1 |
| Vanneta, A | 2 |
| Ajzen, H | 2 |
| Ramos, OL | 3 |
| Moore, RL | 1 |
| Yelamarty, RV | 1 |
| Misawa, H | 1 |
| Scaduto, RC | 1 |
| Pawlush, DG | 1 |
| Elensky, M | 1 |
| Cheung, JY | 1 |
| Mayoux, E | 1 |
| Callens, F | 1 |
| Swynghedauw, B | 1 |
| Charlemagne, D | 1 |
| Dillon, JS | 1 |
| Gu, XH | 1 |
| Nayler, WG | 1 |
| Nielsen, H | 1 |
| Christensen, HR | 1 |
| Christensen, KL | 1 |
| Baandrup, U | 1 |
| Jespersen, LT | 1 |
| de Almeida, JB | 1 |
| Amorim, MP | 1 |
| Portela, J | 1 |
| Cezaretti, ML | 1 |
2 trials available for isradipine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Regression of cardiac hypertrophy in hypertensive patients by long-term treatment with isradipine.
Topics: Adolescent; Adult; Aged; Calcium Channel Blockers; Cardiomegaly; Dihydropyridines; Drug Therapy, Com | 1992 |
Regression of left ventricular hypertrophy in the short-term treatment of hypertension with isradipine.
Topics: Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Electrocardiography; Humans; Hypertension; I | 1991 |
6 other studies available for isradipine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Reversal of left ventricular hypertrophy following treatment of hypertension with isradipine.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Dihydropyrid | 1991 |
Altered Ca2+ dynamics in single cardiac myocytes from renovascular hypertensive rats.
Topics: Analysis of Variance; Animals; Calcium; Calcium Channel Blockers; Cardiomegaly; Cells, Cultured; Fur | 1991 |
Adaptational process of the cardiac Ca2+ channels to pressure overload: biochemical and physiological properties of the dihydropyridine receptors in normal and hypertrophied rat hearts.
Topics: Adaptation, Physiological; Animals; Binding, Competitive; Calcium Channel Blockers; Calcium Channels | 1988 |
Effect of age and of hypertrophy on cardiac Ca2+ antagonist binding sites.
Topics: Aging; Animals; Blood Pressure; Body Weight; Calcium Channels; Cardiomegaly; Cell Membrane; Dihydrop | 1989 |
Antitrophic properties of antihypertensive drugs may depend solely on their blood pressure-lowering capability. A comparative study of isradipine, hydralazine, and metoprolol.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Coronary V | 1989 |
Pump performance after regression of cardiac hypertrophy following treatment of hypertension with isradipine.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiomegaly; Drug Evaluation, Preclinic | 1989 |